Top 100 Richest Indians: India’s Pharma Sector Mints Billionaires
Pharma is on a roll. More than a fifth of the 100 richest billionaires in India have pharma and health care riches, among them half of the eight newcomers, such as Hasmukh Chudgar, whose Intas Pharmaceuticals was recently valued by Temasek at close to $1.4 billion. Entrepreneur P. V. Ramaprasad Reddy, one of three returnees to the list, came back after four years on a threefold jump in shares of his Aurobindo Pharmaceuticals.
Pharma also overtakes steel. Founder of Sun Pharmaceutical Industries, India’s most valuable drug company (market cap: $27 billion), becomes the country’s second-richest person, zipping past steel tycoon Lakshmi Mittal. Sun’s shares surged after it acquired scandal-tainted rival Ranbaxy Laboratories from Japan’s Daiichi Sankyo for $4 billion in April. Deal awaits approvals, including from the Competition Commission of India, which is examining whether it would give Sun a monopoly on some drugs. Some clouds: the U.S. Food & Drug Administration issued an import alert for Sun’s factory in Gujarat, and U.S. arm Caraco pharmaceutical Laboratories recalled three medicines this year.
Desh Bandhu Gupta pharma magnate also known as “DBG” is richer by $1.6 billion taking him to No. 19 on the list with $4.8 billion as shares of his generics firm, Lupin , surged on rising profits. Eyeing global expansion, daughter Vinita and son Nilesh, who run operations, acquired Dutch firm Nanomi, which makes complex injectable products, then entered Mexico with the acquisition of Laboratorios Grin, maker of opthalmic products. Japan is big on their radar; they have a new joint venture with Yoshindo to develop biosimilar drugs for the Japanese.
Business has been good for Pankaj Patel’s Cadila Healthcare which was one of seven Indian firms to get a license from U.S.-based Gilead Sciences to make a low-cost, generic version of its hepatitis C drug Sovaldi, taking his net worth to $3.2 billion.
Yusuf Hamied’s Cipla broke new ground in Februrary when it said that it would help rival Merck to market its HIV drug in India. Eyeing global expansion, it acquired distribution companies in Yemen and Sri Lanka and a stake in Washington D.C.’s Chase pharmaceuticals, which makes drugs for Alzheimer’s disease. Hamied is No. 28 on the list with $3 billion.
P.V. Ramprasad Reddy returns to list on a threefold increase in shares of generics firm Aurobindo Pharma, which he cofounded in 1986 with a relative. The company bounced back after the U.S. FDA lifted an import ban it had imposed in 2011 for manufacturing lapses. Aurobindo’s sales in the U.S. are up, and it is expanding in Europe.
Glenn Saldanha’s Glenmark Pharmaceuticals is expanding its global footprint. In May the company opened a new factory in Switzerland, where it already has a research center, to make drugs for cancer and multiple sclerosis. It’s also building a new factory in the U.S., a market that contributes more than a third to Glenmark’s $1 billion annual revenues. Sister Cheryl, also a pharmacist, oversees corporate affairs.
Newbies on the list brothers Dilip & Anand Surana run Micro Labs, pharma outfit founded in 1973 by their late father Ghewar Chand Surana, who started his career as a pharmaceutical distributor in Chennai. The $372 million (revenues) firm, now headquartered in Bangalore, makes generic drugs that it sells domestically and exports to 30 countries. Micro Labs is in the process of seeking U.S. FDA approval to make generic versions of 75 medicines for eye care, pain management and hypertension. It has invested $33 million in a new factory in the northeast state of Sikkim. The brothers run the company and are targeting sales of $1 billion by 2018.
Sales at Habil Khorakiwala’s pharma outfit Wockhardt were hit by a U.S. FDA import ban on drugs made at 2 of the company’s factories in Maharashtra and by import alerts issued by U.k.’s health regulator. In fiscal year 2014 the company reported a 14% drop in revenues to $810 million while net profits nearly halved to $140 million. Despite these setbacks, Wockhardt’s shares are up by 50% in the past 11 months, restoring Khorakiwala’s billionaire status.
Via : Forbes.com
Tags:
Connect With Us
Related Posts
- Real Estate Act comes into effect: 10 things you need to know about new law ( May 4, 2017 )
- Expats Living in Comfort – Hyderabad, India ( May 4, 2017 )
- MNC queue to Hyderabad grows longer; JP Morgan & IBM look for office space ( June 22, 2016 )
- An Apple in Hyderabad’s IT Garden: CEO Tim Cook’s big announcement Today ( May 19, 2016 )
- Hyderabad May get Disneyland Park ( April 22, 2016 )
- Indian Office Space Absorption Up 11% in Q4: Survey ( April 13, 2016 )
- Cognizant plans to add 8,000 people at Hyderabad facility ( March 9, 2016 )
- Ranked 139 in world, Hyderabad is Best Indian City to Live in ( February 24, 2016 )
- The Platina – Exclusive Commercial Space, Hyderabad ( February 19, 2016 )
- Apple, Inc set to open new $25 million Tech Center in Hyderabad, India by June ( February 16, 2016 )
Recent Posts
Recent Comments
Archives
- February 2018
- October 2017
- May 2017
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- July 2011
- June 2011
- May 2011
- March 2011
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- May 2010
- April 2010
- March 2010
- February 2010
Leave a reply